Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer.
Peter H O'DonnellMatthew I MilowskyDaniel P PetrylakChristopher J HoimesThomas W FlaigNataliya MarHelen H MoonTerence W FriedlanderRana R McKayMehmet Asim BilenSandy SrinivasEarle F BurgessChethan RamamurthySaby GeorgeDaniel M GeynismanSergio BracardaDelphine BorchielliniLionnel GeoffroisJose Pablo Maroto ReyChristiano FerrarioAnne-Sophie CarretYao YuMaria GusevaBlanca Homet MorenoJonathan E RosenbergPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
EV + Pembro showed a high cORR with durable responses as 1L treatment in cisplatin-ineligible patients with la/mUC. Patients who received EV monotherapy had a response and safety profile consistent with previous studies. Adverse events for EV + Pembro were manageable, with no new safety signals observed.